Previous research has confirmed that TRIB3 can inhibit CD8+ T cell infiltration and stimulate the immune evasion through inhibiting the STAT1-CXCL10 axis in colorectal cancer, which is consistent with our results (Shang et al., 2022). Here, TRIB3 is linked to colorectal cancer.